Selected Publications

Academic Article

Year Title Altmetric
2022 A Jack of All Trades: The Role of Pneumococcal Surface Protein A in the Pathogenesis of Streptococcus pneumoniaeFrontiers in Cellular and Infection Microbiology.  12. 2022
2021 Streptococcus pneumoniae binds to host GAPDH on dying lung epithelial cells worsening secondary infection following influenzaCell Reports.  35. 2021
2021 A nanogel-based trivalent PspA nasal vaccine protects macaques from intratracheal challenge with pneumococciVaccine.  39:3353-3364. 2021
2021 Streptococcus pneumoniae binds to host lactate dehydrogenase via pspa and pspc to enhance virulencemBio.  12. 2021
2021 Characterization and Specification of a Trivalent Protein-Based Pneumococcal Vaccine Formulation Using an Adjuvant-Free Nanogel Nasal Delivery SystemMolecular Pharmaceutics.  18:1582-1592. 2021
2021 Pneumococcal capsular phase shift is associated with invasion into cell-to-cell junctions and is inhibited by macrolidesMicrobial Pathogenesis.  153. 2021
2020 A Phase 1 Randomized, Placebo-controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of Inactivated Streptococcus pneumoniae Whole-cell Vaccine in Adults 2020
2020 New Strategy Is Needed to Prevent Pneumococcal Meningitis 2020
2019 PspA facilitates evasion of pneumococci from bactericidal activity of neutrophil extracellular traps (NETs)Microbial Pathogenesis.  136. 2019
2019 Allergic airway sensitization impairs antibacterial IgG antibody responses during bacterial respiratory tract infectionsJournal of Allergy and Clinical Immunology.  143:1183-1197.e7. 2019
2019 The modified surface killing assay distinguishes between protective and nonprotective antibodies to PspAClinical and Vaccine Immunology.  4. 2019
2018 Macrophage Rac2 is required to reduce the severity of cigarette smoke-induced pneumoniaAmerican Journal of Respiratory and Critical Care Medicine.  198:1288-1301. 2018
2018 The diversity of the proline-rich domain of pneumococcal surface protein A (PspA): Potential relevance to a broad-spectrum vaccineVaccine.  36:6834-6843. 2018
2018 Hyperencapsulated mucoid pneumococcal isolates from patients with cystic fibrosis have increased biofilm density and persistence in vivoFEMS Immunology and Medical Microbiology.  76. 2018
2018 Novel immunoprotective proteins of Streptococcus pneumoniae identified by opsonophagocytosis killing screenInfection and Immunity.  86. 2018
2018 Transcutaneous immunization with pneumococcal surface protein A in mice 2018
2017 Neutrophil extracellular traps and fibrin in otitis media: Analysis of human and chinchilla temporal bonesJAMA Otolaryngology-Head and Neck Surgery.  143:990-995. 2017
2017 Dendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniaeMicrobiology and Immunology.  61:195-205. 2017
2017 Inhibition of autolysis by lipase LipA in streptococcus pneumoniae sepsisMolecules and Cells.  40:935-944. 2017
2016 Pneumococcal pep27 mutant immunization stimulates cytokine secretion and confers long-term immunity with a wide range of protection, including against non-typeable strainsVaccine.  34:6481-6492. 2016
2016 The effects of differences in pspA alleles and capsular types on the resistance of Streptococcus pneumoniae to killing by apolactoferrinMicrobial Pathogenesis.  99:209-219. 2016
2016 Pneumolysin plays a key role at the initial step of establishing pneumococcal nasal colonizationFolia Microbiologica.  61:375-383. 2016
2016 PcpA promotes higher levels of infection and modulates recruitment of myeloid-derived suppressor cells during pneumococcal pneumoniaJournal of Immunology.  196:2239-2248. 2016
2016 Free sialic acid acts as a signal that promotes streptococcus pneumoniae invasion of nasal tissue and nonhematogenous invasion of the central nervous systemInfection and Immunity.  84:2607-2615. 2016
2015 The effects of CFTR and mucoid phenotype on susceptibility and innate immune responses in a mouse model of pneumococcal lung diseasePLoS One.  10. 2015
2015 Multivalent pneumococcal protein vaccines comprising pneumolysoid with epitopes/fragments of CbpA and/or PspA elicit strong and broad protectionClinical and Vaccine Immunology.  22:1079-1089. 2015
2015 Nanogel-based pneumococcal surface protein A nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against Streptococcus pneumoniae in macaquesMucosal Immunology.  8:1144-1153. 2015
2015 Current status and perspectives on protein-based pneumococcal vaccinesCritical Reviews in Microbiology.  41:190-200. 2015
2015 ClpL is a chaperone without auxiliary factors 2015
2015 A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella TyphiVaccine.  33:783-788. 2015
2015 A molecular mucosal adjuvant to enhance immunity against pneumococcal infection in the elderly.Immune network.  15:9-15. 2015
2015 Evaluation of a vaccine formulation against Streptococcus pneumoniae based on choline-binding proteins.Clinical and Vaccine Immunology.  22:213-220. 2015
2015 Ethanol-induced alcohol dehydrogenase E (AdhE) potentiates pneumolysin in Streptococcus pneumoniaeInfection and Immunity.  83:108-119. 2015
2015 Streptococcus pneumoniae induces pyroptosis through the regulation of autophagy in murine microgliaOncotarget.  6:44161-44178. 2015
2014 Preparation and testing of a Vi conjugate vaccine using pneumococcal surface protein A (PspA) from Streptococcus pneumoniae as the carrier proteinVaccine.  32:5755-5760. 2014
2014 Protective properties of a fusion pneumococcal surface protein A (PspA) vaccine against pneumococcal challenge by five different PspA clades in miceVaccine.  32:5607-5613. 2014
2014 Mouse, but Not Human, ApoB-100 Lipoprotein Cholesterol Is a Potent Innate Inhibitor of Streptococcus pneumoniae PneumolysinPLoS Pathogens.  10. 2014
2014 Basophil expansion protects against invasive pneumococcal disease in miceJournal of Infectious Diseases.  210:14-24. 2014
2014 Mapping of epitopes recognized by antibodies induced by immunization of mice with PspA and PspCClinical and Vaccine Immunology.  21:940-948. 2014
2014 Pneumococcal PspA and PspC proteins: Potential vaccine candidates for experimental otitis mediaInternational Journal of Pediatric Otorhinolaryngology.  78:1517-1521. 2014
2013 A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA)Vaccine.  32:39-47. 2013
2013 Invasive and Noninvasive Streptococcus pneumoniae Capsule and Surface Protein Diversity following the Use of a Conjugate VaccineClinical and Vaccine Immunology.  20:1711-1718. 2013
2013 Asthma and antibodies to pneumococcal virulence proteins 2013
2013 Modified opsonization, phagocytosis, and killing assays to measure potentially protective antibodies against pneumococcal surface protein AClinical and Vaccine Immunology.  20:1549-1558. 2013
2013 Viability and virulence of pneumolysin, pneumococcal surface protein a, and pneumolysin/pneumococcal surface protein a mutants in the earJAMA Otolaryngology-Head and Neck Surgery.  139:937-943. 2013
2013 Nanogel-based pspa intranasal vaccine prevents invasive disease and nasal colonization by streptococcus pneumoniaeInfection and Immunity.  81:1625-1634. 2013
2013 The link between antibodies to oxldl and natural protection against pneumococci depends on dh gene conservationJournal of Experimental Medicine.  210:875-890. 2013
2013 PspA Family Distribution, Antimicrobial Resistance and Serotype of Streptococcus pneumoniae Isolated from Upper Respiratory Tract Infections in JapanPLoS One.  8. 2013
2013 Inactivated pep27 mutant as an effective mucosal vaccine against a secondary lethal pneumococcal challenge in mice.Clinical and experimental vaccine research.  2:58-65. 2013
2013 Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticlesActa Biomaterialia.  9:8262-8271. 2013
2012 Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholineJournal of Immunology.  189:5327-5335. 2012
2012 The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci In VitroClinical and Vaccine Immunology.  19:1574-1582. 2012
2012 Specific immunization strategies against oxidized low-density lipoprotein: A novel way to reduce nonalcoholic steatohepatitis in miceHepatology.  56:894-903. 2012
2012 Hepatic induction of cholesterol biosynthesis reflects a remote adaptive response to pneumococcal pneumonia 2012
2012 PspA family distribution, unlike capsular serotype, remains unaltered following introduction of the heptavalent pneumococcal conjugate vaccineClinical and Vaccine Immunology.  19:891-896. 2012
2012 Streptococcus pneumoniae pep27 mutant as a live vaccine for serotype-independent protection in miceVaccine.  30:2008-2019. 2012
2012 CCL5-independent helper T lymphocyte responses to immuno-dominant pneumococcal surface protein A epitopesVaccine.  30:1181-1190. 2012
2012 Nontypeable pneumococci can be divided into multiple cps types, including one type expressing the novel gene pspKmBio.  3. 2012
2011 Maternal immunization with pneumococcal surface protein A protects against pneumococcal infections among derived offspringPLoS One.  6. 2011
2011 Elicitation of mucosal immunity by proteins of streptococcus pneumoniaeAdvances in oto-rhino-laryngology.  72:25-27. 2011
2011 Heat-shock protein ClpL/HSP100 increases penicillin tolerance in streptococcus pneumoniaeAdvances in oto-rhino-laryngology.  72:126-128. 2011
2011 Protection of pneumococcal infection by maternal intranasal immunization with pneumococcal surface protein AAdvances in oto-rhino-laryngology.  72:121-125. 2011
2011 The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumoniaInfection and Immunity.  79:2819-2828. 2011
2011 Decrease in penicillin susceptibility due to heat shock protein ClpL in Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy.  55:2714-2728. 2011
2011 Exposure of Thomsen-Friedenreich antigen in Streptococcus pneumoniae infection is dependent on pneumococcal neuraminidase AMicrobial Pathogenesis.  50:343-349. 2011
2011 Serine protease PrtA from Streptococcus pneumoniae plays a role in the killing of S. pneumoniae by apolactoferrinInfection and Immunity.  79:2440-2450. 2011
2011 Streptococcus pneumoniae isolates from middle ear fluid and nasopharynx of children with acute otitis media exhibit phase variationJournal of Clinical Microbiology.  49:1646-1649. 2011
2011 Erratum to " Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1" [Vaccine 28 (42) (2010) 6901-6914]Vaccine.  29:2821. 2011
2011 A combination of Flt3 ligand cDNA and CpG oligodeoxynucleotide as nasal adjuvant elicits protective secretory-IgA immunity to Streptococcus pneumoniae in aged miceJournal of Immunology.  186:2454-2461. 2011
2010 Effect of apolactoferrin on experimental pneumococcal otitis mediaJAMA Otolaryngology-Head and Neck Surgery.  136:1127-1131. 2010
2010 Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1Vaccine.  28:6901-6914. 2010
2010 Secretory-IgA antibodies play an important role in the immunity to Streptococcus pneumoniaeJournal of Immunology.  185:1755-1762. 2010
2010 Complement receptor 1 expression on mouse erythrocytes mediates clearance of Streptococcus pneumoniae by immune adherenceInfection and Immunity.  78:3129-3135. 2010
2010 Importance of CXC chemokine receptor 2 in alveolar neutrophil and exudate macrophage recruitment in response to pneumococcal lung infectionInfection and Immunity.  78:2620-2630. 2010
2010 Influenza A virus facilitates Streptococcus pneumoniae transmission and disease 2010
2010 Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (Pneumococcal surface protein A)Microbial Pathogenesis.  48:205-213. 2010
2010 The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsisInfection and Immunity.  78:2163-2172. 2010
2010 Helper T cell epitope-mapping reveals MHC-peptide binding affinities that correlate with T helper cell responses to pneumococcal surface protein APLoS One.  5. 2010
2010 Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy.  54:707-717. 2010
2009 Virulence of pneumococcal proteins on the inner earJAMA Otolaryngology-Head and Neck Surgery.  135:657-661. 2009
2009 Important role for CC chemokine ligand 2-dependent lung mononuclear phagocyte recruitment to inhibit sepsis in mice infected with Streptococcus pneumoniaeJournal of Immunology.  182:4931-4937. 2009
2009 Mucosal immunization with polyamine transport protein D (PotD) protects mice against nasopharyngeal colonization with Streptococcus pneumoniaeExperimental Biology and Medicine.  234:403-409. 2009
2009 Mucosal vaccination with a multicomponent adenovirus-vectored vaccine protects against Streptococcus pneumoniae infection in the lungFEMS Immunology and Medical Microbiology.  55:346-351. 2009
2009 Antibody to the type 3 capsule facilitates immune adherence of pneumococci to erythrocytes and augments their transfer to macrophagesInfection and Immunity.  77:464-471. 2009
2008 Role of pneumococcal proteins in sensorineural hearing loss due to otitis media 2008
2008 Development of antibodies to PspA families 1 and 2 in children after exposure to Streptococcus pneumoniaeClinical and Vaccine Immunology.  15:1529-1535. 2008
2008 Distribution of pneumococcal surface protein A families 1 and 2 among Streptococcus pneumoniae isolates from children in Finland who had acute otitis media or were nasopharyngeal carriersClinical and Vaccine Immunology.  15:1555-1563. 2008
2008 PIR-B-deficient mice are susceptible to Salmonella infectionJournal of Immunology.  181:4229-4239. 2008
2008 Prospects for use of interleukin-12 as a mucosal adjuvant for vaccination of humans to protect against respiratory pneumococcal infectionVaccine.  26:4893-4903. 2008
2008 Basophils enhance immunological memory responsesNature Immunology.  9:733-742. 2008
2008 Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsisInfection and Immunity.  76:2767-2776. 2008
2008 The round window membrane in otitis media: Effect of pneumococcal proteinsJAMA Otolaryngology-Head and Neck Surgery.  134:658-662. 2008
2008 Effect of high dose oral zinc in mice with severe infection with Streptococcus pneumoniaeInfectious Diseases.  40:363-367. 2008
2008 Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniaeMicrobial Pathogenesis.  44:204-214. 2008
2008 Macrophage turnover kinetics in the lungs of mice infected with Streptococcus pneumoniaeAmerican Journal of Respiratory Cell and Molecular Biology.  38:105-113. 2008
2007 Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement depositionInfection and Immunity.  75:5930-5938. 2007
2007 PspA and PspC minimize immune adherence and transfer of pneumococci from erythrocytes to macrophages through their effects on complement activationInfection and Immunity.  75:5877-5885. 2007
2007 Antibodies to pneumococcal surface protein A families 1 and 2 in serum and saliva of children and the risk of pneumococcal acute otitis mediaJournal of Infectious Diseases.  196:1528-1536. 2007
2007 Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteinsInfection and Immunity.  75:5460-5464. 2007
2007 FMS-like tyrosine kinase 3 ligand aggravates the lung inflammatory response to Streptococcus pneumoniae infection in mice: Role of dendritic cellsJournal of Immunology.  179:3099-3108. 2007
2007 Tumor Suppressor CYLD Regulates Acute Lung Injury in Lethal Streptococcus pneumoniae InfectionsImmunity.  27:349-360. 2007
2007 Structure of a Complex of Human Lactoferrin N-lobe with Pneumococcal Surface Protein A Provides Insight into Microbial Defense MechanismJournal of Molecular Biology.  370:701-713. 2007
2007 Effects of chronic stress and interleukin-10 gene polymorphisms on antibody response to tetanus vaccine in family caregivers of patients with Alzheimer's diseasePsychosomatic Medicine.  69:551-559. 2007
2007 Importance of phosphoinositide 3-kinase γ in the host defense against pneumococcal infectionAmerican Journal of Respiratory and Critical Care Medicine.  175:958-966. 2007
2007 Lung-specific overexpression of CC chemokine ligand (CCL) 2 enhances the host defense to Streptococcus pneumoniae infection in mice: Mole of the CCL2-CCR2 axisJournal of Immunology.  178:5828-5838. 2007
2007 Contributions of pneumolysin, pneumococcal surface protein A (PspA), and PspC to pathogenicity of Streptococcus pneumoniae D39 in a mouse modelInfection and Immunity.  75:1843-1851. 2007
2007 Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniaeInfection and Immunity.  75:350-357. 2007
2006 Serum antibodies to pneumococcal neuraminidase NanA in relation to pneumococcal carriage and acute otitis mediaClinical and Vaccine Immunology.  13:1177-1179. 2006
2006 Pneumococcal surface protein A (PspA) is effective at eliciting T cell-mediated responses during invasive pneumococcal disease in adultsClinical and Experimental Immunology.  145:277-286. 2006
2006 Capsule does not block antibody binding to PspA, a surface virulence protein of Streptococcus pneumoniaeMicrobial Pathogenesis.  40:228-233. 2006
2006 CCL5 modulates pneumococcal immunity and carriageJournal of Immunology.  176:2346-2356. 2006
2006 Mn2+-dependent regulation of multiple genes in Streptococcus pneumoniae through PsaR and the resultant impact on virulenceInfection and Immunity.  74:1171-1180. 2006
2006 Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countriesJournal of Medical Microbiology.  55:215-221. 2006
2006 Bacterial interference of penicillin-sensitive and -resistant Streptococcus pneumoniae by Streptococcus oralis in an adenoid organ culture: Implications for the treatment of recurrent upper respiratory tract infections in children and adults 2006
2005 Nasal colonization with Streptococcus pneumoniae includes subpopulations of surface and invasive pneumococciInfection and Immunity.  73:6945-6951. 2005
2005 Antibodies to the pneumococcal surface protein A, PspA, can be produced in splenectomized mice and can protect splenectomized mice from infection with Streptococcus pneumoniaeVaccine.  23:4257-4262. 2005
2005 Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniaeInfection and Immunity.  73:1304-1312. 2005
2005 Differential PsaA-, PspA-, PspC-, and PdB-specific immune responses in a mouse model of pneumococcal carriageInfection and Immunity.  73:1006-1013. 2005
2005 PspA family typing and PCR-based DNA fingerprinting with BOX A1R primer of pneumococci from the blood of patients in the USA with and without sickle cell diseaseEpidemiology and Infection.  133:173-178. 2005
2005 Relative fitness of fluoroquinolone-resistant Streptococcus pneumoniae 2005
2004 Characterization of antibodies to PspA and PsaA in adults over 50 years of age with invasive pneumococcal diseaseVaccine.  23:789-793. 2004
2004 The virulence function of Streptococcus pneumoniae surface protein A involves inhibition of complement activation and impairment of complement receptor-mediated protectionJournal of Immunology.  173:7506-7512. 2004
2004 Erratum: PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin (Infection and Immunity (2004) 72, 9 (5031-5040))Infection and Immunity.  72:7379. 2004
2004 Lipoprotein PsaA in virulence of Streptococcus pneumoniae: Surface accessibility and role in protection from superoxideInfection and Immunity.  72:5858-5867. 2004
2004 PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrinInfection and Immunity.  72:5031-5040. 2004
2004 Erratum: Pneumococcal carriage results in ganglioside-mediated olfactory tissue infection (Proceeding of the National Academy of Sciences of the United States of America (November 25, 2003) 100, 24 (14363-14367)) 2004
2004 Invasive Streptococcus pneumoniae isolates from Argentinian children: Serotypes, families of pneumococcal surface protein A (PspA) and genetic diversityEpidemiology and Infection.  132:177-184. 2004
2004 Natural materno-fetal transfer of antibodies to PspA and to PsaAClinical and Experimental Immunology.  135:474-477. 2004
2004 Effects of PspA and Antibodies to PspA on Activation and Deposition of Complement on the Pneumococcal SurfaceInfection and Immunity.  72:114-122. 2004
2004 Protection of the elderly from pneumococcal pneumonia with a protein-based vaccine?Mechanisms of Ageing and Development.  125:129-131. 2004
2003 Pneumococcal Surface Protein A Is Expressed in Vivo, and Antibodies to PspA Are Effective for Therapy in a Murine Model of Pneumococcal SepsisInfection and Immunity.  71:7149-7153. 2003
2003 Pneumococcal proteins that may constitute the next generation vaccine for pneumococcal diseaseInternational Congress Series.  1257:27-31. 2003
2003 Pneumococcal carriage results in ganglioside-mediated olfactory tissue infection 2003
2003 Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniaeJournal of Infectious Diseases.  188:339-348. 2003
2003 Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12Infection and Immunity.  71:4780-4788. 2003
2003 Relative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of Streptococcus pneumoniaeInfection and Immunity.  71:4498-4505. 2003
2003 Effects of zinc deficiency and pneumococcal surface protein A immunization on zinc status and the risk of severe infection in miceInfection and Immunity.  71:2009-2013. 2003
2003 Immunogenic protein contaminants in pneumococcal vaccinesJournal of Infectious Diseases.  187:1019-1023. 2003
2003 Regions of PspA/EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection modelInfection and Immunity.  71:1033-1041. 2003
2003 Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniaeInfection and Immunity.  71:75-85. 2003
2002 Complement receptors CD21/35 link innate and protective immunity during Streptococcus pneumoniae infection by regulating IgG3 antibody responsesImmunity.  17:713-723. 2002
2002 Evolution and virulence of serogroup 6 pneumococci on a global scaleJournal of Bacteriology.  184:6367-6375. 2002
2002 Characterization of the dihydrolipoamide dehydrogenase from Streptococcus pneumoniae and its role in pneumococcal infectionMolecular Microbiology.  44:431-448. 2002
2002 Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniaeInfection and Immunity.  70:2526-2534. 2002
2001 Intranasal vaccination with pneumococcal surface protein A and Interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infectionInfection and Immunity.  69:6718-6724. 2001
2001 Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococciInfection and Immunity.  69:4870-4873. 2001
2001 Clones of Streptococcus pneumoniae isolated from nasopharyngeal carriage and invasive disease in young children in central TennesseeJournal of Infectious Diseases.  183:1501-1507. 2001
2001 Characterization of binding of human lactoferrin to pneumococcal surface protein AInfection and Immunity.  69:3372-3381. 2001
2001 The autolytic enzyme lytA of Streptococcus pneumoniae is not responsible for releasing pneumolysinJournal of Bacteriology.  183:3108-3116. 2001
2001 IL-12-mediated increases in protection elicited by pneumococcal and meningococcal conjugate vaccinesVaccine.  19:2020-2028. 2001
2001 Immunologic compensation in a patient with a large IgH constant region deletionJournal of Allergy and Clinical Immunology.  107:1051-1055. 2001
2001 Pneumococcal pulmonary infection, septicaemia and survival in young zinc-depleted mice 2001
2001 Pneumococcal surface protein A of invasive Streptococcus pneumoniae isolates from Colombian children 2001
2001 Streptococcus pneumoniae: New tools for an old pathogenCurrent Opinion in Microbiology.  4:71-77. 2001
2000 The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniaeVaccine.  19. 2000
2000 Erratum: Competition among Streptococcus pneumoniae for intranasal colonization in amouse model (Vaccine (2000) 18 (2895-2901) PII: S0264410X00000463)Vaccine.  19:598. 2000
2000 Competition among Streptococcus pneumoniae for intranasal colonization in a mouse modelVaccine.  18:2895-2901. 2000
2000 Development of a multi-specificity opsonophagocytic killing assayVaccine.  18:2768-2771. 2000
2000 A latex bead-based flow cytometric immunoassay capable of simultaneous typing of multiple pneumococcal serotypes (multibead assay)Clinical and Vaccine Immunology.  7:486-489. 2000
2000 Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniaeInfection and Immunity.  68:3028-3033. 2000
2000 Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA moleculesVaccine.  18:1743-1754. 2000
2000 Purification and characterization of Streptococcus pneumoniae palmitoylated pneumococcal surface adhesin A expressed in Escherichia coliVaccine.  18:1811-1821. 2000
2000 The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infectionVaccine.  18:1707-1711. 2000
2000 Acquired, but not innate, immune responses to Streptococcus pneumoniae are compromised by neutralization of CD40LInfection and Immunity.  68:511-517. 2000
2000 Human antibodies to pneumococcal surface protein A in health and disease 2000
2000 Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniaeInfection and Immunity.  68:796-800. 2000
2000 Diversity of PspA: Mosaic genes and evidence for past recombination in Streptococcus pneumoniaeInfection and Immunity.  68:5889-5900. 2000
2000 Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspAJournal of Infectious Diseases.  182:1694-1701. 2000
2000 Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis mediaJournal of Infectious Diseases.  182:1146-1152. 2000
2000 Pathway analysis in metabolic databases via differential metabolic display (DMD)Bioinformatics.  16:825-836. 2000
2000 Production and characterization of the functional fragment of pneumococcal surface protein AMolecular cell biology research communications : MCBRC.  373:116-125. 2000
1999 The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremiaInfection and Immunity.  67:6533-6542. 1999
1999 In vivo polysaccharide-specific IgG isotype responses to intact Streptococcus pneumoniae are T cell dependent and require CD40- and B7- ligand interactionsJournal of Immunology.  163:659-667. 1999
1999 Effects of active immunization with a pneumococcal surface protein (PspA) and of locally applied antibodies in experimental otitis mediaORL.  61:206-211. 1999
1999 Molecular characterization of a globally distributed lineage of serotype 12F Streptococcus pneumoniae causing invasive diseaseJournal of Infectious Diseases.  179:414-422. 1999
1999 Immunization and protection in pneumococcal otitis media studied in a rat model 1999
1999 Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniaeInfection and Immunity.  67:4720-4724. 1999
1999 Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae infectionsInfection and Immunity.  67:595-601. 1999
1998 A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein AJournal of Immunology.  161:4115-4121. 1998
1998 Comparison of the PspA sequence from Streptococcus pneumoniae EF5668 to the previously identified PspA sequence from strain Rx1 and ability of PspA from EF5668 to elicit protection against pneumococci of different capsular types.Infection and Immunity.  66:4748-4754. 1998
1998 The IS1167 insertion sequence is a phylogenetically informative marker among isolates of serotype 6B Streptococcus pneumoniaeJournal of Molecular Evolution.  47:222-229. 1998
1998 A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein a induces protective responses against Streptococcus pneumoniaeInfection and Immunity.  66:3744-3751. 1998
1998 Enhanced Protective Antibody Responses to PspA after Intranasal or Subcutaneous Injections of PspA Genetically Fused to Granulocyte-Macrophage Colony-Stimulating Factor or Interleukin-2Infection and Immunity.  66:1513-1520. 1998
1998 Pneumococcal diversity: Considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA)Clinical Microbiology Reviews.  11:645-657. 1998
1998 Role of tumor necrosis factor alpha in the host response of mice to bacteremia caused by pneumolysin-deficient Streptococcus pneumoniaeInfection and Immunity.  66:839-842. 1998
1997 Oligonucleotides identify conserved and variable regions of pspA and pspA-like sequences of Streptococcus pneumoniaeGene.  188:279-284. 1997
1997 Development of a model of low-inoculum Streptococcus pneumoniae intrapulmonary infection in infant ratsInfection and Immunity.  65:4701-4704. 1997
1997 Differences in virulence for mice among Streptococcus pneumoniae strains of capsular types 2, 3, 4, 5, and 6 are not attributable to differences in pneumolysin productionInfection and Immunity.  65:1237-1244. 1997
1997 Establishment of a Streptococcus pneumoniae nasopharyngeal colonization model in adult miceMicrobial Pathogenesis.  23:127-137. 1997
1997 Immunization with a plasmid expressing pneumococcal surface protein A (PspA) can elicit protection against fatal infection with Streptococcus pneumoniae 1997
1997 Intranasal immunization of mice with PspA (Pneumococcal surface protein A) can prevent lntranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniaeJournal of Infectious Diseases.  175:839-846. 1997
1997 Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infectionInfection and Immunity.  65:640-644. 1997
1997 PspA and PspC: Their potential for use as pneumococcal vaccines 1997
1997 The hemolytic and complement-activating properties of pneumolysin do not contribute individually to virulence in a pneumococcal bacteremia modelMicrobial Pathogenesis.  23:201-209. 1997
1996 Complement-dependence of c-reactive protein (crp)-mediated protection of mice from streptococcus pneumoniae 1996
1996 Recombinant cholera toxin B subuntt (RCTB) as a mucosal adjuvant 1996
1996 DNA polymorphisms and variant penicillin-binding proteins as evidence that relatively penicillin-resistant pneumococci in Western Canada are clonally relatedJournal of Infectious Diseases.  174:884-888. 1996
1996 Evidence for the simultaneous expression of two PspAs by a clone of capsular serotype 6B Streptococcus pneumoniaeMicrobial Pathogenesis.  21:265-275. 1996
1996 Pneumococcal vaccine response in human immunodeficiency virus-infected patientsJournal of Infectious Diseases.  173:777-778. 1996
1996 PspA, a protection-eliciting pneumococcal protein: Immunogenicity of isolated native PspA in miceVaccine.  14:858-867. 1996
1996 Resistance to mycoplasmal lung disease in mice is a complex genetic traitInfection and Immunity.  64:5326-5331. 1996
1996 Role of complement in C-reactive-protein-mediated protection of mice from Streptococcus pneumoniaeInfection and Immunity.  64:4850-4853. 1996
1996 Systemic and mucosal protective immunity to pneumococcal surface protein AAnnals of the New York Academy of Sciences.  797:118-126. 1996
1996 Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in miceJournal of Infectious Diseases.  173:380-386. 1996
1995 A pneumolysin-negative mutant of Streptococcus pneumoniae causes chronic bacteremia rather than acute sepsis in miceInfection and Immunity.  63:448-455. 1995
1995 Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic miceJournal of Immunology.  155:2557-2563. 1995
1994 Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille calmette-guárin vaccines expressing pneumococcal surface protein AJournal of Experimental Medicine.  180:2277-2286. 1994
1994 Cross‐Reactive Protection Eliciting Epitopes of Pneumococcal Surface Protein AAnnals of the New York Academy of Sciences.  730:361-363. 1994
1994 Localization of protection-eliciting epitopes on pspa of streptococcus pneumoniae between amino acid residues 192 and 260Microbial Pathogenesis.  17:323-337. 1994
1994 The intracellular nature of Salmonella infection during the early stages of mouse typhoid.Immunology series.  60:303-312. 1994
1993 Immunology of tuberculosisMedical Clinics of North America.  77:1235-1251. 1993
1993 The use of monozygotic and dizygotic twins to estimate the effects of inheritance on the levels of immunoglobulin isotypes and antibodies to phosphocholineClinical Immunology.  66:176-180. 1993
1992 Evidence for a Clonal Origin of Relative Penicillin Resistance among Type 9L Pneumococci in Northwestern CanadaJournal of Infectious Diseases.  165:671-675. 1992
1992 A 'safe-site' for Salmonella typhimurium is within splenic polymorphonuclear cellsMicrobial Pathogenesis.  13:181-190. 1992
1992 Analysis of pneumococcal PspA microheterogeneity in SDS polyacrylamide gels and the association of PspA with the cell membraneMicrobial Pathogenesis.  13:343-355. 1992
1992 Geographic Distribution of Penicillin-Resistant Clones of Streptococcus pneumoniae: Characterization by Penicillin-Binding Protein Profile, Surface Protein A Typing, and Multilocus Enzyme AnalysisClinical Infectious Diseases.  15:112-118. 1992
1992 In Vivo Administration of Bryostatin 1, a Protein Kinase C Activator, Decreases Murine Resistance to Salmonella typhimuriumCancer Research.  52:2143-2147. 1992
1992 Molecular localization of variable and conserved regions of pspA and identification of additional pspA homologous sequences in Streptococcus pneumoniaeMicrobial Pathogenesis.  13:261-269. 1992
1992 Mouse antibody to phosphocholine can protect mice from infection with mouse-virulent human isolates of Streptococcus pneumoniaeInfection and Immunity.  60:1957-1962. 1992
1992 Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniaeInfection and Immunity.  60:111-116. 1992
1992 Structural properties and evolutionary relationships of PspA, a surface protein of Streptococcus pneumoniae, as revealed by sequence analysisJournal of Bacteriology.  174:601-609. 1992
1992 Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning of the pspA geneJournal of Bacteriology.  174:610-618. 1992
1991 The salmonella typhlmurium locus mv/a regulates virulence in itys but not ityr mice: Functional mv/a results in avirulence; mutant (nonfunctional) mv/a results in virulenceJournal of Experimental Medicine.  174:1073-1083. 1991
1991 A 'safe-site' for Salmonella typhimurium is within splenic cells during the early phase of infection in miceMicrobial Pathogenesis.  10:297-310. 1991
1991 A 43-kilodalton pneumococcal surface protein, PspA: Isolation, protective abilities, and structural analysis of the amino-terminal sequenceInfection and Immunity.  59:1285-1289. 1991
1991 A hemA mutation renders Salmonella typhimurium avirulent in mice, yet capable of eliciting protection against intravenous infection with S. typhimuriumMicrobial Pathogenesis.  11:289-295. 1991
1991 Antigen-Independent Selection of T15 Idiotype During B-Cell Ontogeny in MiceJournal of Immunology Research.  1:203-212. 1991
1991 Epidemiologic studies of group 9 pneumococci in terms of protein type and 9N versus 9V capsular typeJournal of Infectious Diseases.  163:812-818. 1991
1991 Mouse hepatitis virus strain UAB infection enhances resistance to Salmonella typhimurium in mice by inducing suppression of bacterial growthInfection and Immunity.  59:852-856. 1991
1991 PspA, a surface protein of Streptococcus pneumonia, is capable of eliciting protection against pneumococci of more than one capsular typeInfection and Immunity.  59:222-228. 1991
1990 Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniaeInfection and Immunity.  58:3293-3299. 1990
1990 The primary effect of the Ity locus is on the rate of growth of Salmonella typhimurium that are relatively protected from killingJournal of Immunology.  144:3143-3151. 1990
1990 Variation in the molecular weight of PspA (pneumococcal surface protein A) among Streptococcus pneumoniaeMicrobial Pathogenesis.  8:61-69. 1990
1989 Age-related change in anti-carbohydrate antibody levelsAmerican Journal of Epidemiology.  129:89-96. 1989
1989 Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigensInfection and Immunity.  57:1457-1464. 1989
1989 IgG anti-DNA autoantibodies within an individual autoimmune mouse are the products of clonal selectionJournal of Immunology.  142:4269-4274. 1989
1989 Modulation of resistance to Salmonella typhimurium infection in mice by mouse hepatitis virus (MHV)Microbial Pathogenesis.  6:81-91. 1989
1989 Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniaeInfection and Immunity.  57:2037-2042. 1989
1988 A pneumococcal surface protein (PspB) that exhibits the same protease sensitivity as streptococcal R antigenInfection and Immunity.  56:3001-3003. 1988
1988 Cross-reactive monoclonal antibodies for diagnosis of pneumococcal meningitisJournal of Clinical Microbiology.  26:1635-1640. 1988
1988 Host resistance to mucosal gram-negative infection. Susceptibility of lipopolysaccharide nonresponder miceJournal of Immunology.  140:3180-3185. 1988
1988 Human IgG subclasses and their relation to carbohydrate antigen immunocompetenceJournal of Clinical Laboratory Analysis.  5:241-248. 1988
1988 Protein serotyping of Streptococcus pneumoniae based on reactivity to six monoclonal antibodiesMicrobial Pathogenesis.  5:159-167. 1988
1988 Role of pneumococcal surface protein A in the virulence of Streptococcus pneumoniae.Clinical Infectious Diseases.  10 Suppl 2. 1988
1987 Circulating parasite antigen(s) in lymphatic filariasis: Use of monoclonal antibodies to phosphocholine for immunodiagnosisJournal of Immunology.  138:3454-3460. 1987
1987 Human antibodies to phosphocholine. IgG anti-PC antibodies express restricted numbers of V and C regionsJournal of Immunology.  138:3325-3331. 1987
1987 Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein a (PspA)Journal of Experimental Medicine.  165:381-394. 1987
1987 A protective monoclonal antibody that reacts with a novel antigen of pneumococcal teichoic acidMicrobial Pathogenesis.  3:249-260. 1987
1987 Blood clearance of Streptococcus pneumoniae by C-reactive proteinJournal of Immunology.  138:2598-2603. 1987
1987 Naturally occurring antibodies to phosphocholine as a potential index of antibody responsiveness to polysaccharidesJournal of Infectious Diseases.  155:1307-1314. 1987
1986 Patients with Wiskott-Aldrich Syndrome have normal IgG2 levelsJournal of Immunology.  137:3484-3487. 1986
1986 Analysis of a surface protein of Streptococcus pneumoniae recognised by protective monoclonal antibodiesMicrobial Pathogenesis.  1:519-531. 1986
1986 Effects of in vitro growth phase on the pathogenesis of Salmonella typhimurium in miceMicrobiology.  132:1283-1295. 1986
1986 Genetic approaches to the study of disease resistance: with special emphasis on the use of recombinant inbred mice.Current Topics in Microbiology and Immunology.  124:21-35. 1986
1986 Genetic control of the susceptibility to pneumococcal infection.Current Topics in Microbiology and Immunology.  124:103-120. 1986
1986 Genetic mapping of novel virulence determinants of Salmonella typhimurium to the region between trpD and supDMicrobial Pathogenesis.  1:115-124. 1986
1986 Independence of macrophage activation and expression of the alleles of the Ity (immunity to typhimurium) locusMicrobial Pathogenesis.  1:33-41. 1986
1986 Natural and vaccine-related immunity to streptococcus pneumoniaeJournal of Infectious Diseases.  154:245-256. 1986
1986 Salmonella typhimurium virulence genes necessary to exploit the Ity(s/s) genotype of the mouseInfection and Immunity.  51:872-878. 1986
1986 Transformation of encapsulated Streptococcus pneumoniaeJournal of Bacteriology.  168:1463-1465. 1986
1985 Induction of germ-line anti-α1-3 dextran antibody responses in mice by members of the enterobacteriaceae familyJournal of Immunology.  135:3468-3472. 1985
1985 Genetic factors in host resistance to urinary tract infection 1985
1985 Genetic factors in host resistance to urinary tract infection 1985
1985 Antiidiotypic antibodiesMethods in Enzymology.  VOL. 116:174-189. 1985
1985 Blood clearance of pneumococci by C-reactive protein 1985
1985 Evidence for separate genetic defects in C3H/HeJ and C3HeB/FeJ mice, that affect susceptibility to gram-negative infectionsJournal of Immunology.  134:4118-4122. 1985
1985 Monoclonal antibodies against idiotopes on human anti-hapten antibodies 1985
1985 The ability of Salmonella typhimurium to produce the siderophore enterobactin is not a virulence factor in mouse typhoidInfection and Immunity.  50:392-397. 1985
1984 Blood clearance by anti-phosphocholine antibodies as a mechanism of protection in experimental pneumococcal bacteremiaJournal of Immunology.  133:3308-3312. 1984
1984 The effects of subclass on the ability of anti-phosphocholine antibodies to protect mice from fatal infection with Streptococcus pneumoniaeThe Journal of molecular and cellular immunology : JMCI.  1:305-309. 1984
1984 Monoclonal antibodies to Salmonella lipopolysaccharide: Anti-O-polysaccharide antibodies protect C3H mice against challenge with virulent Salmonella typhimuriumJournal of Immunology.  133:950-957. 1984
1984 Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus PneumoniaeJournal of Experimental Medicine.  160:386-397. 1984
1984 Lack of IgA subclass restriction in antibody response to phosphorylcholine, β lactoglobulin and tetanus toxoidImmunology.  53:419-426. 1984
1984 Monoclonal antibodies against surface polypeptides on mouse virulent strains of Streptococcus pneumoniae 1984
1984 The J606-GAC subset of antibody is composed of the products of several - different variable region gene segments 1984
1984 The effects of idiotype on the ability of IgG1 antiphosphorylcholine antibodies to protect mice from fatal infection with Streptococcus pneumoniaeEuropean Journal of Immunology.  14:1027-1030. 1984
1984 The mouse heavy chain variable region marker, J606-GAC, is not restricted to particular B cell isotypes or subsetsJournal of Immunology.  132:783-786. 1984
1983 DEFICIENT IgA SYNTHESIS VIEWED IN THE CONTEXT OF NORMAL DEVELOPMENT OF IgA B‐CELLSAnnals of the New York Academy of Sciences.  409:461-468. 1983
1983 Epidemiological studies of Streptococcus pneumoniae in infants: Development of antibody to phosphocholineJournal of Clinical Microbiology.  18:1102-1107. 1983
1983 Resistance to Streptococcus pneumoniae is induced by a phosphocholine-protein conjugateJournal of Immunology.  130:2871-2875. 1983
1983 Ten percent of normal B cells and plasma cells share A V(H) determinants) (J606-GAC) with a distinct subset of murine V(H)III plasmacytomasJournal of Immunology.  130:2423-2428. 1983
1982 Erratum: Mouse IgG3 antibodies are highly protective against infection with Streptococcuspneumoniae (Nature (1981) 294, (88-90))Nature.  295:438. 1982
1982 Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus PneumoniaeJournal of Experimental Medicine.  156:1177-1185. 1982
1982 Streptococcal group A carbohydrate has properties of both a thymus-independent (TI-2) and a thymus-dependent antigenJournal of Immunology.  128:2032-2035. 1982
1982 Anti-DNA autoantibodies in (NZB x NZW)F1 mice are clonally heterogeneous, but the majority share a common idiotypeJournal of Immunology.  128:668-674. 1982
1982 Estimate of the light chain repertoire size of fetal and adult BALB/cJ and CBA/J miceJournal of Immunology.  129:673-677. 1982
1982 Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in miceJournal of Immunology.  128:2374-2376. 1982
1982 Protection of mice from infection with Streptococcus pneumoniae by anti-phosphocholine antibodyInfection and Immunity.  36:184-188. 1982
1981 Mouse IgG3 antibodies are highly protective against infection with Streptococcus pneumoniaeNature.  294:88-90. 1981
1981 Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 Streptococcus pneumoniaeJournal of Experimental Medicine.  153:694-705. 1981
1981 A genetic locus responsible for salmonella susceptibility in BSVS mice is not responsible for the limited T-dependent immune responsiveness of BSVS miceJournal of Immunology.  127:906-911. 1981
1981 A simple method for estimating the probable numbers of different antibodies by examining the repeat frequencies of sequences or isoelectric focusing patternsMolecular Immunology.  18:29-38. 1981
1981 Phagocytosis and killing of Salmonella typhimurium by peritoneal exudate cellsInfection and Immunity.  33:380-388. 1981
1980 Clonal nature of the immune response. II. The effect of immunization of clonal commitmentJournal of Experimental Medicine.  152:151-160. 1980
1980 Isoelectric focusing of immunoglobulins: Improved methodologyImmunotechnology : an international journal of immunological engineering.  33:101-115. 1980
1979 Immune response deficiency of BSVS mice. II. Generalized deficiency to thymus‐dependent antigensEuropean Journal of Immunology.  9:255-261. 1979
1978 Light chain diversity of murine anti-streptococcal antibodies: IgC(H)-linked effects on L chain expressionJournal of Immunology.  121:149-158. 1978
1978 Subclass restriction of murine anti-carbohydrate antibodiesJournal of Immunology.  121:566-572. 1978
1978 Analysis of the diversity of murine antibodies to dextran B1355. III. Idiotypic and spectrotypic correlationsEuropean Journal of Immunology.  8:352-359. 1978
1977 Analysis of the diversity of murine antibodies to dextran B1355. II. Demonstration of multiple idiotypes with variable expression in several strainsJournal of Immunology.  119:1406-1412. 1977
1977 Complete sharing of light chain spectrotypes by murine IgM and IgG anti streptococcal antibodiesJournal of Immunology.  118:2161-2166. 1977
1977 Immune response deficiency of BSVS mice - I. Identification of Ir gene differences between A/J and BSVS mice in the antistreptococcal group A carbohydrate responseImmunogenetics.  4:381-392. 1977
1976 Analysis of the diversity of murine antibodies to dextran B1355. I. Generation of a large, pauci clonal response by a bacterial vaccineJournal of Immunology.  117:569-575. 1976
1975 Clonal dominance. I. Restricted nature of the IgM antibody response to group A streptococcal carbohydrate in miceJournal of Experimental Medicine.  141:1291-1307. 1975
1975 Detection of isoelectric focused antibody by autoradiography and hemolysis of antigen-coated erythrocytes. A comparison of methodsImmunotechnology : an international journal of immunological engineering.  8:363-372. 1975
1974 Mouse strain specific idiotypy and interstrain idiotypic cross reactionsJournal of Immunology.  113:522-530. 1974
1974 Idiotypic uniformity of cell surface immunoglobulin in chronic lymphocytic leukemia: Evidence for monoclonal proliferationJournal of Experimental Medicine.  140:1416-1420. 1974
1974 Restriction of early IgM antibody response to streptococcal group A carbohydrate 1974
1972 Mouse antibodies to group A streptococcal carbohydrate; use of idiotypy to detect inbred strain specificity and to monitor spleen cell transfer in syngenetic mice.Journal of Immunology.  109:1311-1320. 1972


Year Title Altmetric
2019 Pneumococcal Vaccines 2019
2019 Pneumococcal vaccines.  362-377. 2019
2012 Pneumococcal common proteins and other vaccine strategies..  459-469. 2012
2012 Analysis of the diversity of murine antibodies to a (1-3) dextran..  295-308. 2012
2008 Animal Models of Invasive Pneumococcal Disease.  47-58. 2008
2005 Respiratory bacterial vaccines.  905-921. 2005
2004 Pneumococcal proteins and their potential use in pneumococcal vaccines.  459-469. 2004
2003 Streptococcus pneumoniae vaccines.  294-310. 2003
2003 Immunity to Extracellular Bacteria:.  1263-1284. 2003

Research Overview

  • The Briles lab focuses on the use of virulence factors of Streptococcus pneumoniae in the development of human pneumococcal vaccines. Pneumococci are a major cause of pneumonia, serious meningitis, otitis media, sepsis, and bacteremia in man. Our approach uses both bacterial and animal genetics to identify and study important mechanisms in protection and virulence. We identified a cell surface protein of pneumococci, PspA, which is important for pneumococcal virulence and is probably the most exposed protein on the pneumococcal surface. We do pre-clinical research and collaborate on clinical research with PspA and other pneumococcal proteins that will hopefully lead to a vaccine for young children and the elderly. Studies are underway to characterize the protection-eliciting portion of PspAs from human isolates of pneumococci, and to assemble these into an effective human vaccine with other protection-eliciting pneumococcal proteins. We are/have been studying the mode of action of several pneumococcal virulence factors including PspA, pneumolysin, PspC, PsaA, PcpA, and NanA. We believe that epitopes of some of or all of these proteins will be used to create a vaccine to prevent pneumococcal carriage and invasive disease. We are also developing in vivo killing assays to guide the development of such a vaccine for use in humans. Our collaborations at UAB are primarily with the labs of M. Nahm, C. Orihuela, and W. Swords. Our work involves collaborations with vaccine development groups in Japan, China, the United Kingdom, Brazil, and Australia.
  • Principal Investigator On

  • Comparative Efficacy of Non Capsular Pneumococcal Vaccines in Animal Models  awarded by PATH VACCINE SOLUTIONS
  • Comparative Efficacy of Non Capsular Pneumococcal Vaccines in Animal Models - Fifth Project Plan  awarded by PATH VACCINE SOLUTIONS
  • Comparative Efficacy of Non Capsular Pneumococcal Vaccines in Animal Models - Fourth Project Plan  awarded by PATH VACCINE SOLUTIONS
  • Comparative Efficacy of Non Capsular Pneumococcal Vaccines in Animal Models - Third Project Plan  awarded by PATH VACCINE SOLUTIONS
  • Detection of Protective Antibody with ModOPKA Functional Assay  awarded by PATH VACCINE SOLUTIONS
  • Development of a Diagnostic Test for Pneumococcal Pneumonia  awarded by PATH FOUNDATION
  • Effect of Middle Ear Inflammation on the Inner Ear  awarded by University of Minnesota
  • Eight Project Plan - VAC-010  awarded by PATH VACCINE SOLUTIONS
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by SANOFI DIAGNOSTICS PASTEUR, INC.
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC.
  • Protection Elicited by Active Immunity to Goldstein Antigen ProtGBSP14  awarded by PATH VACCINE SOLUTIONS
  • PspA Mechanisms of Humoral Immunity, Functional Assays, and Optimal Vaccine Constructs  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • PspA: A Potential Pneumococcal Vaccine Component  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Seventh Project Plan, Rabbit Antisera to R. Goldstein's Antigens  awarded by PATH VACCINE SOLUTIONS
  • Sixth Project Plan, Detection of Protective Antibody with ModOPKA Functional Assay  awarded by PATH VACCINE SOLUTIONS
  • The Role of PcpA in the Mechanism of Virulence and Protective Immunity  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Trivalent Pneumococcal Protein Vaccine (PPC): Preclinical Optimization  awarded by PATH FOUNDATION
  • Vaccine Potential of the Proline-Rich Domain of Pneumococcal Surface Protein A  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Education And Training

  • Doctor of Philosophy in Immunology, The Rockefeller University 1973
  • Full Name

  • David Briles